Increased PTX3 gene expression was reported in ovarian cancer with stromal signature [37], in aggressive breast cancer with distant bone metastases [38–40], in prostate cancer [41], in glioblastoma [42], in anaplastic thyroid carcinoma [43], and in soft tissue liposarcoma [44]. This evidence concerns the gene PTX3 and prostate carcinoma.